Astellas Pharma Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Astellas Pharma Inc. - Product Pipeline Review - 2016', provides an overview of the Astellas Pharma Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc. - The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Astellas Pharma Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Astellas Pharma Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Astellas Pharma Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Astellas Pharma Inc. Snapshot 7 Astellas Pharma Inc. Overview 7 Key Information 7 Key Facts 7 Astellas Pharma Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Astellas Pharma Inc. - Pipeline Review 16 Pipeline Products by Stage of Development 16 Pipeline Products - Monotherapy 17 Pipeline Products - Combination Treatment Modalities 18 Pipeline Products - Partnered Products 19 Pipeline Products - Out-Licensed Products 22 Astellas Pharma Inc. - Pipeline Products Glance 24 Astellas Pharma Inc. - Late Stage Pipeline Products 24 Astellas Pharma Inc. - Clinical Stage Pipeline Products 27 Astellas Pharma Inc. - Early Stage Pipeline Products 29 Astellas Pharma Inc. - Drug Profiles 33 linaclotide 33 solifenacin succinate 36 tacrolimus ER 38 (ipragliflozin + sitagliptin phosphate) 39 (mirabegron + solifenacin succinate) 40 amenamevir 42 ASP-0113 43 bendamustine hydrochloride 44 degarelix acetate 47 enzalutamide 49 evolocumab 53 fidaxomicin 56 gilteritinib fumarate 59 mirabegron ER 61 naquotinib mesylate 63 peficitinib hydrobromide 64 quetiapine fumarate ER 66 romosozumab 67 roxadustat 69 AGS-16C3F 72 ASP-1707 73 ASP-3662 74 ASP-7962 75 ASP-8232 76 erlotinib hydrochloride 77 FG-2216 80 ipragliflozin 82 linsitinib 86 MA09-hRPE 89 regadenoson 91 blinatumomab 93 AGS-67E 97 ASG-15ME 99 ASP-0819 100 ASP-2205 101 ASP-2905 102 ASP-4132 103 ASP-4345 104 ASP-5094 105 ASP-5878 106 ASP-6282 107 ASP-6294 108 ASP-7266 109 ASP-7398 110 ASP-8062 111 enfortumab vedotin 112 OSI-930 113 AS-1069562 114 AS-1669058 115 AS-1940477 116 AS-2034178 117 AS-2077715 118 AS-2444697 119 AS-2521780 120 AS-2575959 121 AS-2715348 122 AS-2795440 123 AS-288640100 124 ASP-1017 125 ASP-1645 126 ASP-3258 127 ASP-5736 128 ASP-6537 129 ASP-7663 130 ASP-9133 131 ASP-9726 132 FK-886 133 Gene Therapy to Activate mVChR1 for Retinits Pigmentosa 135 KB-425796C 136 Monoclonal Antibody Conjugates for Oncology 137 OSI-296 138 Small Molecule 2 for Epilepsy 140 Small Molecule 3 for Epilepsy 141 Small Molecule 4 for Epilepsy 142 Small Molecule for Epilepsy 143 Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain 144 Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer 145 Small Molecule to Inhibit JAK3 for Heart Transplantation 146 Small Molecule to Inhibit PDE10A for Schizophrenia 147 Small Molecule to Inhibit TAK1 for Ovarian Cancer 148 Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes 149 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine 150 Small Molecules to Inhibit DAAO for Cognitive Disorders 151 Small Molecules to Inhibit RANKL for Osteoclastogenesis 152 Stem Cell Therapy for Autoimmune Diseases 153 Stem Cell Therapy for Corneal Blindness 154 Stem Cell Therapy for Glaucoma 155 Stem Cell Therapy for Ophthalmic Disorders 156 UMN-0901 157 AS-1468240 158 Drugs for Pancreatic Cancer 159 KB-425796A 160 Monoclonal Antibodies for Oncology 161 Small Molecules for Non-Neuromuscular and Neuromuscular Disorders 162 Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders 163 Small Molecules to Inhibit ACK1 for Oncology 164 Astellas Pharma Inc. - Pipeline Analysis 165 Astellas Pharma Inc. - Pipeline Products by Target 165 Astellas Pharma Inc. - Pipeline Products by Route of Administration 175 Astellas Pharma Inc. - Pipeline Products by Molecule Type 176 Astellas Pharma Inc. - Pipeline Products by Mechanism of Action 177 Astellas Pharma Inc. - Recent Pipeline Updates 184 Astellas Pharma Inc. - Dormant Projects 256 Astellas Pharma Inc. - Discontinued Pipeline Products 258 Discontinued Pipeline Product Profiles 260 Astellas Pharma Inc. - Company Statement 268 Astellas Pharma Inc. - Locations And Subsidiaries 269 Head Office 269 Other Locations & Subsidiaries 269 Astellas Pharma Inc. - Key Manufacturing Facilities 275 Appendix 276 Methodology 276 Coverage 276 Secondary Research 276 Primary Research 276 Expert Panel Validation 276 Contact Us 276 Disclaimer 277
List of Tables
Astellas Pharma Inc., Key Information 15 Astellas Pharma Inc., Key Facts 15 Astellas Pharma Inc. - Pipeline by Indication, 2016 17 Astellas Pharma Inc. - Pipeline by Stage of Development, 2016 24 Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016 25 Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2016 26 Astellas Pharma Inc. - Partnered Products in Pipeline, 2016 27 Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2016 28 Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016 30 Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 31 Astellas Pharma Inc. - Pre-Registration, 2016 32 Astellas Pharma Inc. - Filing rejected/Withdrawn, 2016 33 Astellas Pharma Inc. - Phase III, 2016 34 Astellas Pharma Inc. - Phase II, 2016 35 Astellas Pharma Inc. - Phase I, 2016 36 Astellas Pharma Inc. - IND/CTA Filed, 2016 37 Astellas Pharma Inc. - Preclinical, 2016 38 Astellas Pharma Inc. - Discovery, 2016 40 Astellas Pharma Inc. - Pipeline by Target, 2016 173 Astellas Pharma Inc. - Pipeline by Route of Administration, 2016 183 Astellas Pharma Inc. - Pipeline by Molecule Type, 2016 184 Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2016 185 Astellas Pharma Inc. - Recent Pipeline Updates, 2016 192 Astellas Pharma Inc. - Dormant Developmental Projects,2016 264 Astellas Pharma Inc. - Discontinued Pipeline Products, 2016 266 Astellas Pharma Inc., Other Locations 277 Astellas Pharma Inc., Subsidiaries 278 Astellas Pharma Inc., Key Manufacturing Facilities 283
List of Figures
Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2016 17 Astellas Pharma Inc. - Pipeline by Stage of Development, 2016 24 Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016 25 Astellas Pharma Inc. - Partnered Products in Pipeline, 2016 27 Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016 30 Astellas Pharma Inc. - Pipeline by Top 10 Target, 2016 173 Astellas Pharma Inc. - Pipeline by Route of Administration, 2016 183 Astellas Pharma Inc. - Pipeline by Molecule Type, 2016 184 Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 185
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.